Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
media
posted on 2023-12-20, 18:28 authored by Adis journals on behalf of:, Pedram Hamrah, Mina Massaro-Giordano, David Schanzlin, Edward Holland, Gregg Berdy, Giovanni Goisis, Georgea Pasedis, Flavio MantelliThe above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
